Clinical Trial Update: T-regulatory Cell Depletion with E7777 Combined with Pembrolizumab in Recurrent or Metastatic Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating regulatory T-cell depletion with E7777 in combination with pembrolizumab for recurrent or metastatic epithelial ovarian ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Ovarian Cancer

Drugs mentioned

• E7777 (E7777)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Alexander B Olawaiye, MD | Conditions: Epithelial Ovarian Cancer | Phase 1, Phase 2 | Status: RECRUITING